insights_auto
Why is BANB down 3.46%?
Dive Deeperchevron_right
BANB:SWX
BACHEM HOLDING AG
CHFÂ 80.80
arrow_downward
-3.46%(-2.90) 1D
Nov 3, 5:30:38 PM GMT+1 · CHF
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BANB...
Open
CHFÂ 82.20
High
CHFÂ 82.40
Low
CHFÂ 80.60
Mkt. cap
6.06B
Avg. vol.
85.13K
Volume
118.79K
Dividend
1.11%
Quarterly dividend
CHFÂ 0.22
Ex-dividend date
May 4, 2026
P/E ratio
40.74
52-wk high
CHFÂ 86.00
52-wk low
CHFÂ 48.52
EPS
CHFÂ 1.98
Shares outstanding
75.00M
No. of employees
3K
Open
CHFÂ 82.20
High
CHFÂ 82.40
Low
CHFÂ 80.60
Mkt. cap
6.06B
Avg. vol.
85.13K
Volume
118.79K
Dividend
1.11%
Quarterly dividend
CHFÂ 0.22
Ex-dividend date
May 4, 2026
P/E ratio
40.74
52-wk high
CHFÂ 86.00
52-wk low
CHFÂ 48.52
EPS
CHFÂ 1.98
Shares outstanding
75.00M
No. of employees
3K
News stories
From web sources and news partners
شبكة تواصل الإخبارية
·
46 minutes ago
The S&P 500 Fell in Both September and October for Only the 17th Time Since 1950. Here's What Usually Followed.
TradingView
·
9 hours ago
Stocks Supported by Strength in Chipmakers
MarketWatch
·
4 hours ago
S&P 500 is looking over the edge of a technical cliff — what happens if it falls off?
FXStreet
·
1 hour ago
What is the smart money doing behind the S&P 500? [Video]
Profile
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients. The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz, Vista and Torrance, and St Helens, as well as a sales and distribution site in Tokyo.
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million. Wikipedia
About BACHEM HOLDING AG